RxDoctor Payments Data

Joseph Husney, MD

Internal Medicine · Brooklyn, NYNPI 1770699647

Payments from drug & device makers

$4,266in general payments, 2019–2025

Across 203 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$592
  • AstraZeneca$571
  • GSK$472
  • E.r. Squibb & Sons, L.L.C.$374
  • Gilead$318
  • Merck$294
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,266100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,266 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$199,412
Medicare patients
201
Services billed
2,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin120$75,419
EliquisApixaban93$74,428
JanumetSitagliptin Phos/Metformin Hcl62$44,309
FarxigaDapagliflozin Propanediol61$40,893
XareltoRivaroxaban46$31,114
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$29,366
TrulicityDulaglutide29$28,199
RybelsusSemaglutide22$22,645
JanuviaSitagliptin Phosphate34$18,288
OzempicSemaglutide16$17,984
MounjaroTirzepatide15$16,722
LinzessLinaclotide19$10,347
JentaduetoLinagliptin/Metformin Hcl15$8,280
LyricaPregabalin24$6,829
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto$19$83,699135 claims
PfizerEliquis, Lyrica$182$81,257117 claims
MerckJanumet, Januvia$294$62,59696 claims
Lilly USA, LLCTrulicity, Mounjaro$592$44,92144 claims
AstraZenecaFarxiga$571$40,89361 claims
Novo NordiskRybelsus, Ozempic$20$40,62938 claims
Johnson & JohnsonXarelto$39$31,11446 claims
GSKTrelegy Ellipta$472$29,36636 claims
AbbVieLinzess, Synthroid$191$12,17748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →